Business Segment, Geographic, and Concentration Risk Information (Tables)

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Summary of Segment Information

Segment information is as follows (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Net (loss) income attributable to Athenex, Inc.:
Oncology Innovation Platform	$	(37,639	)	$	(22,558	)	$	(65,985	)	$	(83,836	)
Global Supply Chain Platform		(6,089	)		(1,564	)		(16,780	)		(4,693	)
Commercial Platform		(2,443	)		848			(7,562	)		(14,358	)
Total consolidated net loss attributable to Athenex, Inc.	$	(46,171	)	$	(23,274	)	$	(90,327	)	$	(102,887	)

Summary of Revenue by Segments

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Total revenue:
Oncology Innovation Platform	$	5,117		$	205		$	30,532		$	1,208
Global Supply Chain Platform		7,092			8,601			17,991			19,407
Commercial Platform		7,315			7,378			23,006			9,274
Total revenue for reportable segments		19,524			16,184			71,529			29,889
Intersegment revenue		(1,096	)		(2,190	)		(3,700	)		(6,719	)
Total consolidated revenue	$	18,428		$	13,994		$	67,829		$	23,170

Summary of Revenue by Product Group

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Total revenue by product group:
API sales	$	3,690	$	5,345	$	9,538	$	10,369
Medical device sales		1,322		562		2,342		1,128
Contract manufacturing revenue		17		250		412		934
Commercial product sales		8,280		7,505		25,092		9,547
License fees		5,000		—		30,000		500
Consulting revenue		96		60		278		256
Grant revenue		23		272		167		436
Total consolidated revenue	$	18,428	$	13,994	$	67,829	$	23,170

Summary of Depreciation, Amortization and Assets by Segment

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Total depreciation and amortization:
Oncology Innovation Platform	$	174	$	130	$	505	$	342
Global Supply Chain Platform		490		548		1,185		1,569
Commercial Platform		245		243		734		674
Total consolidated depreciation and amortization	$	909	$	921	$	2,424	$	2,585

	September 30,		December 31,
	2018		2017
Total assets:
Oncology Innovation Platform	$	164,480	$	65,966
Global Supply Chain Platform		51,327		51,128
Commercial Platform		28,660		23,319
Total consolidated assets	$	244,467	$	140,413

Summary of Revenue by Geographical Segment

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Total revenue:
United States	$	9,559	$	8,114	$	27,405	$	11,056
Spain		5,000		—		30,000		—
India		259		3,015		1,701		5,275
Austria		2,227		964		5,102		2,682
China		306		1,038		1,917		2,267
Other foreign countries		1,077		863		1,704		1,890
Total consolidated revenue	$	18,428	$	13,994	$	67,829	$	23,170

Summary of Property and Equipment by Geographical Segment

	September 30,		December 31,
	2018		2017
Total property and equipment, net:
United States	$	6,458	$	5,305
China		4,716		4,346
Total consolidated property and equipment, net	$	11,174	$	9,651

Summary of Customer Revenue and Accounts Receivable Concentration

Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Percentage of total revenue by customer:
Customer A		27	%		—	%		44	%		—	%
Customer B		13	%		5	%		9	%		4	%
Customer C		12	%		16	%		13	%		11	%
Customer D		11	%		5	%		8	%		3	%
Customer E		10	%		7	%		6	%		11	%
Customer F		1	%		18	%		2	%		20	%

	September 30,			December 31,
	2018			2017
Percentage of total accounts receivable by customer:
Customer A		27	%		18	%
Customer B		20	%		10	%
Customer C		13	%		6	%
Customer D		10	%		4	%
Customer E		—	%		26	%
Customer F		—	%		13	%